The role of endoglin in hepatocellular carcinoma

Kuo Shyang Jeng, I. Shyan Sheen, Shu Sheng Lin, Chuen Miin Leu, Chiung Fang Chang*

*此作品的通信作者

研究成果: Review article同行評審

14 引文 斯高帕斯(Scopus)

摘要

Endoglin (CD105) is a type-1 integral transmembrane glycoprotein and coreceptor for transforming growth factor-β (TGF-β) ligands. The endoglin/TGF-β signaling pathway regulates hemostasis, cell proliferation/migration, extracellular matrix (ECM) synthesis and angiogenesis. Angiogenesis contributes to early progression, invasion, postoperative recurrence, and metastasis in hepatocellular carcinoma (HCC), one of the most widespread malignancies globally. Endoglin is overexpressed in newly formed HCC microvessels. It increases microvessel density in cirrhotic and regenerative HCC nodules. In addition, circulating endoglin is present in HCC patients, suggesting potential for use as a diagnostic or prognostic factor. HCC angiogenesis is dynamic and endoglin expression varies by stage. TRC105 (carotuximab) is an antibody against endoglin, and three of its clinical trials were related to liver diseases. A partial response was achieved when combining TRC105 with sorafenib. Although antiangiogenic therapy still carries some risks, combination therapy with endoglin inhibitors or other targeted therapies holds promise.

原文English
文章編號3208
頁(從 - 到)1-12
頁數12
期刊International Journal Of Molecular Sciences
22
發行號6
DOIs
出版狀態Published - 2 3月 2021

指紋

深入研究「The role of endoglin in hepatocellular carcinoma」主題。共同形成了獨特的指紋。

引用此